LLY

909.85

+2.28%↑

JNJ

243.48

+0.6%↑

ABBV

216.2

+1.64%↑

NVS

151.21

+0.83%↑

MRK

119.78

+0.99%↑

LLY

909.85

+2.28%↑

JNJ

243.48

+0.6%↑

ABBV

216.2

+1.64%↑

NVS

151.21

+0.83%↑

MRK

119.78

+0.99%↑

LLY

909.85

+2.28%↑

JNJ

243.48

+0.6%↑

ABBV

216.2

+1.64%↑

NVS

151.21

+0.83%↑

MRK

119.78

+0.99%↑

LLY

909.85

+2.28%↑

JNJ

243.48

+0.6%↑

ABBV

216.2

+1.64%↑

NVS

151.21

+0.83%↑

MRK

119.78

+0.99%↑

LLY

909.85

+2.28%↑

JNJ

243.48

+0.6%↑

ABBV

216.2

+1.64%↑

NVS

151.21

+0.83%↑

MRK

119.78

+0.99%↑

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

24.51 4.52

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

23.37

Máximo

23.87

Métricas clave
By Trading Economics
Ingresos	-85K 53M
Ventas	4.2M 153M
P/B Media del Sector	13.881 57.05
BPA	0.68
Margen de beneficios	34.53
Empleados	182
EBITDA	612K 81M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+47.44% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-97M 2.9B
Apertura anterior	19.99
Cierre anterior	24.51

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

111 / 349 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 mar 2026, 23:15 UTC

Noticias de Eventos Importantes

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 mar 2026, 22:36 UTC

Noticias de Eventos Importantes

Australian Government Rules Out Boots on the Ground in the Middle East

30 mar 2026, 22:13 UTC

Adquisiciones, fusiones, absorciones

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 mar 2026, 21:00 UTC

Ganancias

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 mar 2026, 20:15 UTC

Noticias de Eventos Importantes

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 mar 2026, 23:40 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 mar 2026, 23:40 UTC

Charlas de Mercado

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 mar 2026, 23:36 UTC

Charlas de Mercado

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 mar 2026, 23:12 UTC

Charlas de Mercado

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 mar 2026, 22:49 UTC

Charlas de Mercado

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 mar 2026, 22:44 UTC

Charlas de Mercado

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 mar 2026, 22:43 UTC

Charlas de Mercado

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 mar 2026, 22:42 UTC

Charlas de Mercado

South32 Should Go for Growth, Says New Bull -- Market Talk

30 mar 2026, 22:18 UTC

Charlas de Mercado

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 mar 2026, 22:05 UTC

Charlas de Mercado

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 mar 2026, 21:58 UTC

Adquisiciones, fusiones, absorciones

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 mar 2026, 21:39 UTC

Adquisiciones, fusiones, absorciones

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 mar 2026, 21:38 UTC

Adquisiciones, fusiones, absorciones

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 mar 2026, 21:36 UTC

Adquisiciones, fusiones, absorciones

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 mar 2026, 21:25 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 mar 2026, 21:25 UTC

Charlas de Mercado

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 mar 2026, 21:03 UTC

Adquisiciones, fusiones, absorciones

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 mar 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

30 mar 2026, 20:09 UTC

Ganancias

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 mar 2026, 20:00 UTC

Noticias de Eventos Importantes

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

47.44% repunte

Estimación a 12 Meses

Media 34.5 USD 47.44%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

111 / 349 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.